Yusuke Muranishi

Papers

Total Citations

H-Index

About

Yusuke Muranishi is a thoracic surgeon and clinical researcher whose work focuses on the intersection of immunotherapy and surgical oncology for non-small cell lung cancer (NSCLC). His primary research areas include salvage surgery after immune checkpoint inhibitor (ICI) therapy, multimodal treatment strategies for initially unresectable lung cancer, and perioperative outcomes in advanced thoracic malignancies. Muranishi’s most notable contribution is his landmark 2024 study, "Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer," which provided the first systematic investigation into the safety, feasibility, and oncologic outcomes of surgical resection following ICI treatment. This work has rapidly accumulated 6 citations, establishing a critical evidence base for a paradigm shift in managing advanced NSCLC—demonstrating that salvage surgery can offer durable local control and potential cure in patients who convert from unresectable to resectable disease after immunotherapy. His findings directly inform clinical decision-making for multidisciplinary teams, bridging medical oncology and thoracic surgery. Muranishi’s research is widely recognized for its translational impact, helping to define new treatment pathways for patients with initially inoperable lung cancer. He continues to advance the field through ongoing studies on patient selection, surgical timing, and long-term survival after ICI-based conversion therapy.